746452
Sulfato de magnesio
anhydrous, free-flowing, Redi-Dri™, ReagentPlus®, ≥99.5%
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
MgSO4
Número CAS:
Peso molecular:
120.37
NACRES:
NA.21
PubChem Substance ID:
UNSPSC Code:
12352302
EC Number:
231-298-2
MDL number:
Assay:
≥99.5%
Grade:
anhydrous
Form:
powder
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlegrade
anhydrous
Quality Level
agency
suitable for SM 5210
vapor density
<0.01 (vs air)
vapor pressure
<0.1 mmHg ( 20 °C)
product line
ReagentPlus®, Redi-Dri™
assay
≥99.5%
form
powder
quality
free-flowing
pH
~7.9 (25 °C, 50 g/L)
SMILES string
[Mg++].[O-]S([O-])(=O)=O
InChI
1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
InChI key
CSNNHWWHGAXBCP-UHFFFAOYSA-L
General description
Magnesium sulfate is a magnesium salt with tocolytic ability. Its role to induce an analgesic effect during intraoperative and postoperative periods has been investigated. It is reported to prevent eclampsia. Its ability to remove water from water-miscible solvents by salting-out phase separation has been studied.
Application
Magnesium sulfate may be used as a drying agent for organic extracts.
Features and Benefits
- Increased efficiency – Eliminate time and effort of loosening hardened powders
- Safety – Avoid risks of using tools of force to break up clumps
- Economy – Faster preparation and solvation increase productivity and reduce costs
- Assured quality – Excellent, expert-tested quality with no anti-caking agents
- Flexible volumes – Available from research amounts to scale-up quantities
Legal Information
ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany
Redi-Dri is a trademark of Sigma-Aldrich Co. LLC
Still not finding the right product?
Explore all of our products under Sulfato de magnesio
Clase de almacenamiento
13 - Non Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Lex W Doyle
Current opinion in pediatrics, 24(2), 154-159 (2012-01-10)
Antenatal magnesium sulfate may reduce the excessive rates of cerebral palsy in survivors of very preterm birth. There are five randomized controlled trials of magnesium sulfate therapy given to the mother prior to very preterm birth which have reported neurological
Robert J Floor et al.
Chembiochem : a European journal of chemical biology, 15(11), 1660-1672 (2014-07-01)
We explored the use of a computational design framework for the stabilization of the haloalkane dehalogenase LinB. Energy calculations, disulfide bond design, molecular dynamics simulations, and rational inspection of mutant structures predicted many stabilizing mutations. Screening of these in small
Lex W Doyle et al.
Obstetrics and gynecology, 113(6), 1327-1333 (2009-05-23)
To systematically review rates of neurologic outcomes reported in childhood for the preterm fetus exposed to antenatal magnesium sulfate. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register, CENTRAL (The Cochrane Library 2008, Issue 3), relevant references from retrieved